Atavistik raises $120M for bleeding disorder, blood cancer drugsnews2025-12-18T13:59:04+00:00December 18th, 2025|Endpoints News|
Steve Paul’s post-Karuna act draws $165M to schizophrenia biotech Syremisnews2025-12-18T11:30:05+00:00December 18th, 2025|Endpoints News|
Addition Therapeutics raises $106.5M for all RNA ‘jumping gene’ therapiesnews2025-12-17T13:22:29+00:00December 17th, 2025|Endpoints News|
Verge Genomics’ ALS drug fails as biotech shifts to partner modelnews2025-12-16T20:04:38+00:00December 16th, 2025|Endpoints News|
Mythic Therapeutics shuts down, ends ADC trial as funding dries upnews2025-12-16T18:51:01+00:00December 16th, 2025|Endpoints News|
Chronic pain biotech Ambros Therapeutics emerges with $125M and Vivek Ramaswamy on boardnews2025-12-16T13:06:56+00:00December 16th, 2025|Endpoints News|
Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesitynews2025-12-16T13:00:32+00:00December 16th, 2025|Endpoints News|
Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfrontnews2025-12-15T14:51:09+00:00December 15th, 2025|Endpoints News|
Sobi to buy gout biotech Arthrosi for $950M upfrontnews2025-12-15T08:47:48+00:00December 15th, 2025|Endpoints News|
GSK spins out corporate VC fund focused on bioelectronic technews2025-12-12T14:11:50+00:00December 12th, 2025|Endpoints News|
